Aneurysmal subarachnoid haemorrhage (SAH) is a devastating disease associated with high mortality and poor outcome in many survivors. Aggressive treatment by a comprehensive multidisciplinary team is associated with improved outcome, but the intensive care management of SAH presents significant challenges. Multimodal neuromonitoring may detect secondary insults before irreversible neuronal damage has occurred, and is increasingly being used to guide treatment. This article reviews current trends in the intensive care management of SAH from aspects of initial resuscitation to recent developments in the prevention and management of complications, including delayed cerebral ischaemia. Evidence from clinical trials and recent consensus guidance is reviewed.
Introduction
Aneurysmal subarachnoid haemorrhage (SAH) is a devastating disease with an incidence of 2 to 22.5 per 100,000 population. 1 Although it accounts for only 3-5% of strokes overall, it is responsible for a large loss of productive life years because it commonly occurs in younger people, peaking between 40 and 60 years. One-month case fatality is as high as 35% even in high income countries, and around one third of those who survive need life-long care, with a further third having residual cognitive impairment that affects their functional status and quality of life. 2 Mortality is higher and good functional outcome less likely in patients with poor grade SAH, those over 65 years of age and those who develop complications. 3, 4 Early aggressive resuscitation and multidisciplinary intensive care management is associated with improved outcomes 5 and consensus guidelines for the intensive care management of SAH have recently been published. 6 
Pathophysiology
Approximately 85% of cases of SAH are related to spontaneous rupture of an intracranial aneurysm in the basal cerebral arteries, leading to escape of blood at high pressure into the subarachnoid space. Non-aneurysmal peri-mesencephalic bleeds, with haemorrhage centred anterior to the midbrain or pons, account for 10% of cases. A further 5% are divided between multiple, rarer pathologies, including traumatic causes. Several SAH grading scales have been described but the World Federation of Neurological Surgeons (WFNS) scale, based on the Glasgow Coma Scale (GCS) and presence of motor deficits, is most commonly used because of its simplicity and objectivity. 7 Such scales guide management that is influenced by the severity of the SAH, and also offer an early estimation of prognosis.
In severe SAH, intracranial pressure (ICP) may rise to levels approaching or above mean arterial blood pressure (ABP), leading to a temporary arrest of the cerebral circulation and unconsciousness. 8 Global cerebral oedema causing widespread ischaemic neuronal injury may ensue and this is associated with poor outcome. 9 There are multiple cerebral metabolic repercussions of SAH and these are also recognised as independent factors influencing outcome. 10, 11 
Clinical presentation and diagnosis
The classic history of SAH is one of sudden onset headache, often described as the 'worst imaginable.' However, this is nondiscriminatory and only around 1% of patients presenting to emergency departments with headache will subsequently be diagnosed with SAH. 12 Other clinical features range from neck stiffness, vomiting and altered consciousness, to seizures, loss of consciousness and sudden death.
Standard non-contrast CT is the investigation of choice and is diagnostic in up to 95% of cases. A normal scan, particularly early after the ictus, does not exclude SAH and in the presence of a good history and normal scan, lumbar puncture should be performed. 12 Confirmation of the presence of red blood cells or their metabolites in the cerebrospinal fluid identifies an additional 3% of patients who subsequently have an aneurysm detected by cerebral angiography. 13 The diagnostic sensitivity of lumbar puncture is increased when performed at least six to 12 hours after the initial ictus, although this results in a delay in initiating treatment.
Acute treatment
Acute treatment is similar to that for any critically ill patient and focuses on maintenance of adequate ventilation and haemodynamic stabilisation. In addition, attention must be given to maintenance of cerebral perfusion, minimising the risk of re-bleeding and achieving a rapid diagnosis. This presents many challenges in the emergency department as multiple goals must be achieved simultaneously, often remote from neuroscience input. Unconscious patients, or those with a falling GCS, should be intubated and ventilated to maintain PaO 2 >13.0 kPa and PaCO 2 4.5-5.0 kPa. Short-term moderate hyperventilation (PaCO 2 4.0-4.5 kPa) may be indicated if intracranial hypertension is suspected, eg in the presence of hydrocephalus, an expanding intraparenchymal haematoma or cerebral oedema. Hypertension is a normal response to SAH, although high blood pressure increases the risk of re-bleeding, whereas excessive reductions in blood pressure risk the development of cerebral ischaemia. Extreme hypertension should be treated cautiously with short-acting agents but modest elevations in blood pressure (mean ABP <110 mm Hg) do not require treatment. 6 Prior to securing the aneurysm, premorbid blood pressure should be used to refine pressure targets, although mean ABP is usually maintained between 90-110 mm Hg. Hypotension should be meticulously avoided.
Once the poor grade patient is stabilised, immediate transfer to a neurosciences centre should be undertaken. Stable patients with good grade SAH should be transferred urgently so that definitive treatment can be undertaken within 24 hours of the ictus. Recent guidance recommends that patients with SAH should be treated at high-volume centres with timely access to multidisciplinary teams since this is associated with improved outcomes. 6 
Diagnostic imaging
A repeat CT scan may be necessary to confirm the diagnosis, identify acute hydrocephalus and allow treatment planning of the causative aneurysm (Figure 1) . CT angiography (CTA) is an appropriate first step to identify the anatomical territory of the aneurysm and interpretation by an experienced neuroradiologist reliably identifies aneurysms >4 mm. 14 Formal four-vessel digital subtraction angiography (DSA) remains the investigation of choice in many centres and is required if CTA is equivocal.
Additional imaging can inform treatment planning, particularly in poor grade patients. Perfusion CT quantifies regional and global hypoperfusion 15 and various magnetic resonance imaging (MRI) sequences identify ischaemia and provide a wealth of information on metabolic and perfusion variables. 16 
Securing the aneurysm
Early aneurysm control reduces the risk of re-bleeding and allows higher ABP to prevent or treat cerebral hypoperfusion. The widespread use of endovascular coiling of intracranial aneurysms represents a major advance in the treatment of SAH because minimally invasive and effective treatment is possible even in the sickest patients. The International Subarachnoid Aneurysm Trial (ISAT) compared endovascular and surgical techniques and confirmed an improvement in early survival in selected patients receiving endovascular therapy, with a small excess of late bleeds. 17 ISAT has been criticised for many reasons. 18 In brief, 69% of the 9,559 patients eligible for recruitment into the study were excluded because of lack of equipoise. Since almost all intracranial aneurysms can be treated by surgery, it follows that a large proportion of patients was excluded because of an assessment that their aneurysm was not suitable for coiling. There was a rarity of posterior circulation and middle cerebral artery aneurysms in ISAT and, because posterior circulation and middle cerebral artery aneurysms are preferentially treated by coiling and clipping respectively, this also raises the possibility of sample bias. However, the proportion of cases that are unsuitable for endovascular treatment is likely to be much lower today because of advances in technology and expertise since 2002. The majority of aneurysms are now primarily treated by endovascular options, but coiling is still not a replacement for surgical treatment. Aneurysms in selected locations, those >25 mm, those with a wide neck or with branches arising from the aneurysm, may not be amenable to coiling, and some may have a worse outcome with coiling compared to clipping. 18 Each patient and aneurysm is different and a treatment decision must be made for each patient individually by a multidisciplinary team.
Re-bleeding
Re-bleeding was previously the primary cause of death following poor grade SAH but rates have dramatically reduced since the shift towards early securing of the ruptured aneurysm. The greatest risk of re-bleeding occurs within the first 24 hours and is highest in those with the poorest grade. The overall re-bleeding rate is 4-7%, with a 1.5% risk per day for up to two weeks after the ictus.
Acute antifibrinolytic therapy may reduce the risk of re-bleeding by as much as 40% but is not associated with improved outcome, possibly because of micro-thrombosisrelated cerebral ischaemia. 19 The short-term use of antifibrinolytics should currently be considered only in those at high risk of re-bleeding in whom definitive treatment of the aneurysm is delayed. 20
Intensive care management
Following securing of the aneurysm, the intensive care management of SAH involves treatment of acute complications such as hydrocephalus requiring external ventricular drainage (Figure 1 ), optimisation of systemic physiology and the prevention or treatment of delayed cerebral ischaemia (DCI) and non-neurological complications. Aggressive treatment is now recommended for all but the most hopeless cases since substantial numbers of even poor grade patients may do well following comprehensive multidisciplinary therapy. 5,21 Nevertheless, some patients will have a poor outcome despite maximal therapy and it is essential that early aggressive treatment is linked to compassionate end-of-life care if a satisfactory degree of clinical recovery does not occur within an appropriate time scale.
Monitoring
Multimodal cerebral monitoring, including ICP, brain tissue oxygen tension, transcranial Doppler ultrasonography (TCD), cerebral microdialysis and electrophysiological monitoring, allows integration of multiple aspects of cerebral physiology with systemic physiological variables. 23, 24 In this way individualised patient care can be delivered with the aim of preventing or minimising secondary ischaemic injury. After SAH, this is particularly relevant in terms of balancing cerebral oxygen supply and demand in the setting of acute injury, and in the subsequent detection and treatment of DCI. 25 Intracranial pressure is increasingly being monitored, particularly in poor grade patients, as the need for aggressive management of intracranial hypertension is undisputed. 22, 26 This can be achieved via a ventricular catheter placed to relieve hydrocephalus or via a standard transducertipped intraparenchymal monitor. Changes in brain tissue biochemistry and oxygenation may identify impending or actual cerebral hypoxia/ischaemia before changes in other monitoring modalities or the patient' s clinical status are apparent. 27 Although this extends the potential treatment window, it remains to be determined whether interventions directed towards normalisation of these biomarkers will result in improved clinical outcome. Impaired vascular reactivity has been linked with poor outcome after SAH and integration of cerebral monitoring signals can be used to derive indices of cerebrovascular reactivity. 28 There is recent interest in electrophysiological monitoring after SAH. Nonconvulsive seizures and status epilepticus occur more frequently than previously recognised and continuous electroencephalography has a key role in their detection and therefore management. 29 Cortical spreading depolarisations (SDs) are pathological events characterised by near-complete sustained depolarisation of neurons and astrocytes that result in secondary injury related to mitochondrial damage, accumulation of intracellular calcium and excitotoxicity. SDs may occur in up to 70% of patients after SAH 30 but their detection currently requires placement of an electrode strip directly onto the brain surface, thus limiting routine monitoring on the ICU.
There is currently no consensus regarding multimodal monitoring in patients with SAH and the majority of modalities have not been thoroughly validated nor their influence on outcome determined. 23 
Delayed cerebral ischaemia
DCI is a term applied to any neurological deterioration, including focal neurological deficits and altered consciousness, which persists for more than one hour and cannot be explained by other abnormalities identified by radiographic, laboratory or electrophysiological investigations. It may be unrecognised clinically in some patients because of their poor clinical grade or the concurrent administration of sedatives. DCI occurs in around 30% of patients, peaks between four and 10 days after the ictus and persists for several days. It is second only to the initial haemorrhage as a cause of morbidity and mortality after SAH. 
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Pathophysiology
Although DCI has been attributed to cerebral vasospasm, the exact relationship between the two is unclear. DCI can occur in the absence of vasospasm and vice versa, and ischaemia often involves more than one vascular territory. 31 Other mechanisms contributing to DCI include vascular dysautoregulation, microthrombi, direct neurotoxic effects and cortical SDs. 5 Diagnosis DCI is detected clinically by a reduction in level of consciousness with or without a focal neurologic deficit. In unconscious or sedated patients, several methods can be used to identify DCI but DSA remains the diagnostic gold standard ( Table 1) . The risks and time requirements of this invasive intervention mean that alternative and complementary diagnostic tools such as CT angiography and CT perfusion, which together allow characterisation of vascular anatomy and associated cerebral perfusion abnormalities, are increasingly being used. 32 Transcranial Doppler measures blood flow velocity (FV) in basal cerebral arteries, and consecutive TCD examinations should be carried out after SAH; blood flow velocity (FV) >120-140 cm/s, or FV increases >50 cm/s/day from baseline, are generally accepted to be indicative of developing or established DCI. However, there is considerable interindividual variation and a recent study analysing 1,877 TCD examinations found that almost 40% of patients with clinical evidence of DCI never had FVs that exceeded 120 cm/s. 33 Treatment decisions should not therefore be based on TCD findings alone. As changes in the cerebral blood flow (CBF) affect FV, the Lindegaard ratio, which compares FV in the ipsilateral middle and internal carotid arteries and is unaffected by changes in cerebral blood flow (CBF), is often used. A ratio >3.0 is indicative of vasospasm and values >6 suggest severe spasm.
Multimodal monitoring, particularly brain tissue PO 2 and cerebral microdialysis, might also identify vasospasm and identify treatment targets, although these are focal techniques and the monitoring probe must be accurately located in the region of interest. 27, 34 
Treatment
Since DCI is delayed and may be reversible, it is an obvious target for preventative and treatment strategies ( Table 2 ).
Nimodipine
All patients should receive enteral nimodipine, a specific antagonist of L-type voltage-gated calcium channels, 60 mg four-hourly immediately after diagnosis. This reduces the incidence of DCI and improves outcome. 35 The mechanisms by which nimodipine reduces DCI are uncertain because it does not reverse angiographic vasospasm in humans. Although intravenous nimodipine is sometimes used in critically ill patients, this route of administration is unproven and care must be taken to avoid hypotension.
Triple H therapy
Triple H therapy, hypervolaemia, haemodilution and hypertension, has been widely used to prevent and treat DCI but the combination has never been tested in a randomised controlled trial. While fluid therapy is a key component of the management of SAH, prophylactic hypervolaemic therapy is not effective in raising CBF or improving neurological outcome, and there is some evidence of harm from overly aggressive filling. 36 Recent consensus guidance recommends that euvolaemia rather than hypervolaemia should be the target for both prophylaxis and treatment of DCI, and that haemodilution should not be used. 37 Isotonic crystalloids are the fluids of choice, although hypertonic saline solutions have a place in patients who are hyponatraemic. In the presence of a secured aneurysm, maintenance of ABP at supra-normal levels is the mainstay of treatment of DCI. 38 Pressure should be increased in a stepwise fashion, guided by assessment of neurological function, neuromonitoring or radiological evidence of improved perfusion. 6 In the presence of adequate 
Endovascular therapies
Endovascular treatment options for cerebral vasospasm are effective in some cases which are resistant to medical therapy. 6 Balloon angioplasty has been widely used to reverse vasospasm in major basal arteries, but it may also be effective for more distal spasm. 40 Angioplasty is often combined with the selective intra-arterial administration of vasodilators, including verapamil, nimodipine, nicardipine, milrinone and fasudil, although comparisons with conventional (non-interventional) therapy have been made. 41 
Novel treatments
Since DCI is unlikely to be related only to vasospasm, several pharmacological agents have been tested in this context. 42, 43 Statins have multiple beneficial effects on vascular function and have been used to prevent and treat DCI. However, a recent meta-analysis found that statins have no significant effect on the incidence of DCI, poor neurological outcome or mortality. 44 Current guidance recommends that patients already on statins should have these drugs continued but that the introduction of acute statin therapy should only be considered in carefully selected patients at high risk of DCI. 45 The ongoing STASH trial is designed to determine the outcome effects of statins after SAH (http://clinicaltrials.gov/ct2/show/ NCT00731627). Magnesium reverses cerebral arterial spasm in animal models of SAH, but the only randomised clinical trial demonstrated no beneficial effect on the incidence of DCI and cerebral infarction or on clinical outcome. 46 A subsequent post hoc analysis showed that high plasma magnesium levels are associated with worse clinical outcomes 47 and although hypomagnesaemia should be avoided, induced hypermagnesaemia is therefore not recommended. 46 Endothelin has a key role in maintaining vascular tone and endothelin-A antagonists such as clazosentan have been studied but have not been shown to reduce mortality or improve neurological outcome after SAH. 48 Since activation of the coagulation cascade and microthrombosis might play a role in DCI, attention has also focussed on agents affecting these variables. A Cochrane review suggested a non-significant trend towards improved outcome in patients treated with antiplatelet agents but this was accompanied by an increased risk of haemorrhagic complications. 49 Two large randomised controlled trials provided contradictory results about the effect of enoxaparin on outcome after SAH 50, 51 and, although antifibrinolytic agents reduce the rates of rebleeding-related mortality, this is offset by a higher rate of DCI. 19 
Seizure control
Seizures occur in approximately 20% of patients after SAH but treatment remains controversial. Actual seizures must be treated aggressively but universal prophylaxis is not recommended. Three days of treatment offers similar seizure prevention and better outcome than longer-term therapy. 52 Phenytoin should be avoided because of associated cognitive effects and poor outcome and a short course of levetiracetam is recommended. 53 
Non-neurological complications
Non-neurological complications are common after SAH and independently associated with poor outcome (Table 3) . 54 In a study from a single centre, 79% of patients developed at least one medical complication 4 and, in the Cooperative Aneurysm Study, the proportion of deaths related to non-neurological complications was 23% (similar to that of vasospasm at 22%). 55 As they are independently associated with poor outcome after SAH, non-neurological complications represent potentially modifiable risk factors and early recognition and prompt intervention might therefore improve outcome. 56 However, the intensive care management of non-neurological organ dysfunction and failure presents significant challenges because optimum treatment for the failing systemic organ system may have potentially adverse effects on the injured brain. 21 
Cardiopulmonary complications
Cardiac complications are common and associated with DCI and poor outcome. 57 These are manifest as an abnormal ECG, elevated cardiac troponin (cTnI), and a spectrum of ventricular dysfunction collectively referred to as the neurogenic stunned myocardium (NSM) syndrome. 58 ECG abnormalities are extremely common after SAH ( Table 4) , elevation of cardiac cTnI occurs in 20-40% of patients and left ventricular (LV) dysfunction in around 18%.
NSM is caused by excessive noradrenaline release from myocardial sympathetic nerve terminals resulting in a physiological myocardial denervation in the presence of normal coronary perfusion. 59 This results in a characteristic pattern of LV regional wall motion abnormalities involving the basal and middle portions of the anteroseptal and anterior ventricular walls with relative apical sparing, reflecting the distribution of sympathetic nerves rather than specific vascular territories. 60 The degree of myocardial dysfunction and damage is related to the severity of the SAH 61 and, although LV dysfunction is usually temporary, it is associated with higher mortality after SAH. Takotsubo cardiomyopathy, also referred to as left apical ballooning, is a transient, virtually global LV dysfunction characterised by apical and mid-ventricular akinesia with relative sparing of the basal segment. 62 It may occur as a response to sudden physical or emotional stress, when it generally has a benign prognosis, but it is also a rare cause of ventricular dysfunction after SAH, when it is associated with increased mortality. NSM may be associated with minimal clinical effects but, in severe cases, can lead to cardiogenic shock and pulmonary oedema. 59 Cardiovascular dysfunction often resolves spontaneously after a variable period, emphasising the importance of general supportive intensive care during periods of instability.
Modification of the sympathetic response might limit cardiac dysfunction after SAH and patients on chronic antihypertensive therapy have a lower incidence of SAH-associated cardiac injury. 63 However, there is no strong evidence to recommend this line of therapy and, in any case, the risk of hypotension is a cause for concern. Inotropic support with dobutamine and, less so, milrinone is beneficial in the setting of low cardiac output, despite a mechanism of action similar to the cause of cardiac injury. 64 Pure vasopressors are often necessary to maintain cerebral perfusion but their adverse effects on cardiac work risks potentiating myocardial injury. Characterising cardiac performance using echocardiography and continuous cardiac output monitoring may be useful in guiding therapy in patients with symptomatic NSM.
Neurogenic pulmonary oedema (NPO) and pneumonia are common after SAH and associated with adverse outcome. 65, 66 The mechanism of NPO is controversial but likely to be related to neurogenic-mediated catecholamine release that leads to both hydrostatic and permeability oedema. Many patients with SAH and acute lung injury can be managed safely using lung protective ventilation strategies, but in others there can be a conflict between treating the lungs and the injured brain. 67 A ventilation strategy that maximises oxygenation while balancing risks to the lungs and injured brain should be identified individually for each patient. 66, 68 Dysnatraemia Hyponatraemia after SAH is often related to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), although the cerebral salt wasting (CSW) syndrome and iatrogenic haemodilution can be implicated. 69 As plasma tonicity reduces, fluid shifts may precipitate cerebral oedema and neurological sequelae. SIADH occurs because of excess antidiuretic hormone secretion, causing water retention, volume overload and dilutional hyponatraemia. CSW on the other hand is associated with raised atrial and brain natiuretic peptide and excessive renal sodium and water loss, leading to circulating volume contraction. It is important to distinguish between SIADH and CSW syndrome, since the treatment of the two is diametrically opposed. 70 Electrolyte-free water restriction, initially to 1,000-1,500 mL/day, forms the usual mainstay of treatment of SIADH but this may worsen cardiovascular instability and increase the risk of cerebral hypoperfusion after SAH. Consideration should be given to the use of hypertonic saline (1.8%) in hyponatraemic patients with a high risk of DCI. Pharmacological therapies such as demeclocycline and ADH-receptor antagonists may have a place in some patients. The primary treatment of CSW syndrome is volume and sodium resuscitation. Fludrocortisone or hydrocortisone may also be used to limit the natiuresis but care must be taken to monitor for hypokalaemia and hyperglycaemia. 6 Hypernatraemia independently increases the risk of adverse cardiac outcome and death after SAH and patients with hypernatraemia should be monitored for evidence of cardiac dysfunction. 71 
Fever
Fever occurs in up to 70% of patients, is more common in poor grade SAH and associated with worse outcome. 72 While an infective cause should be excluded (pneumonia is particularly common), the fever can be related to the hypothalamic effects of subarachnoid blood. Paracetamol is first line therapy for fever control and although active cooling to normothermia has been associated with improved outcome, the adverse effects of shivering 73 might offset its benefits.
Glycaemic control
Hyperglycaemia is common after SAH, occurring in around 30% of patients, and is associated with adverse outcome. 74 Tight glycaemic control is not recommended since it can be associated with increased cerebral metabolic crises. 75 Current practice has adopted more relaxed glycaemic targets (typically 6-11 mmol/L) limiting overly-aggressive insulin administration and minimising the risk of hypoglycaemia and its known adverse effects on the injured brain. 76 
Anaemia
Anaemia is very common and associated with poor outcome after SAH, although transfusion is itself similarly associated with adverse outcome effects. 77 Current guidance recommends that packed red cells be administered to maintain haemoglobin concentration between 8-10 g/dL, although higher thresholds might be appropriate in patients at high risk of DCI. 6 
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